Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.

ABSTRACT:

Background

Understanding mechanisms underlying specific chemotherapeutic responses in subtypes of cancer may improve identification of treatment strategies most likely to benefit particular patients. For example, triple-negative breast cancer (TNBC) patients have variable response to the chemotherapeutic agent cisplatin. Understanding the basis of treatment response in cancer subtypes will lead to more informed decisions about selection of treatment strategies.

Methods

In this study we used an integrative functional genomics approach to investigate the molecular mechanisms underlying known cisplatin-response differences among subtypes of TNBC. To identify changes in gene expression that could explain mechanisms of resistance, we examined 102 evolutionarily conserved cisplati

SUBMITTER: Hill DP 

PROVIDER: S-EPMC6829976 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature